clarithromycin
Sources réglementaires consultées
Indications approuvées
- Infections respiratoires, cutanées et odontogènes dues à des germes sensibles, éradication de H. pylori en association et infections mycobactériennes selon des schémas spécifiques.
Contre-indications
Absolues
- Hypersensibilité à la clarithromycine ou aux macrolides ; QT long, arythmie ventriculaire, hypokaliémie ou hypomagnésémie ; antécédent d’ictère ou de dysfonction hépatique lié à la clarithromycine ; insuffisance hépatique sévère associée à une insuffisance rénale ; et traitement par astémizole, terfénadine, cisapride, dompéridone, pimozide, lurasidone, ticagrélor, ivabradine, ranolazine, midazolam oral, ergotamine/dihydroergotamine, lovastatine, simvastatine ou lomitapide. La colchicine est contre-indiquée en cas d’insuffisance rénale ou hépatique.
Mises en garde cliniques
- Il peut prolonger le QT et provoquer des torsades de pointes ; éviter en cas de QT long, d’hypokaliémie ou d’hypomagnésémie, de bradycardie significative et avec d’autres médicaments allongeant le QT. — CIMA/AEMPS, ficha técnica 67638
- Mise en garde majeure · Il peut provoquer une hépatite cholestatique, une nécrose hépatique ou une insuffisance hépatique ; arrêter en cas de signes de dysfonction hépatique. — CIMA/AEMPS, ficha técnica 67638
- Mise en garde majeure · Une diarrhée et une colite à Clostridioides difficile peuvent survenir pendant ou après le traitement ; évaluer toute diarrhée importante et arrêter si le diagnostic est confirmé. — CIMA/AEMPS, ficha técnica 67638
Interactions médicamenteuses
- SévèreSimvastatine et lovastatine
Mécanisme: La forte inhibition du CYP3A4 augmente le risque de myopathie et de rhabdomyolyse.
Recommandation: Ne pas administrer ensemble ; arrêter pendant le traitement.
CIMA/AEMPS, ficha técnica 67638
- ModéréeAlcaloïdes de l’ergot, pimozide, cisapride et médicaments allongeant le QT
Mécanisme: Il peut provoquer un ergotisme ou une arythmie ventriculaire sévère.
Recommandation: Ne pas administrer ensemble.
CIMA/AEMPS, ficha técnica 67638
- SévèreColchicine
Mécanisme: L’inhibition du CYP3A4 et de la P-gp augmente l’exposition et la toxicité de la colchicine, surtout en insuffisance rénale ou hépatique.
Recommandation: Éviter en cas d’insuffisance rénale ou hépatique ; si elle est utilisée, réduire la dose et surveiller la toxicité.
CIMA/AEMPS, ficha técnica 67638
Effets indésirables
Communs (≥1%)
Nausées, douleurs abdominales, diarrhée et vomissements
Rares mais graves
Anaphylaxie, hépatotoxicité sévère, arythmie ventriculaire et réactions cutanées sévères
Grossesse et allaitement
Éviter pendant la grossesse, surtout au premier trimestre, sauf en l’absence d’alternative plus sûre. Interrompre l’allaitement pendant le traitement.
Bibliographie récente (PubMed)
Helicobacter pylori is a prevalent, global infectious disease that causes dyspepsia, peptic ulcer disease, and gastric cancer. The American College of Gastroenterology commissioned this clinical practice guideline (CPG) to inform the evidence-based management of patients with H. pylori infection in North America. This CPG used Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology to systematically analyze 11 Population, Intervention, Comparison, and Outcome questions and generate recommendations. Where evidence was insufficient or the topic did not lend itself to GRADE, expert consensus was used to create 6 key concepts. For treatment-naive patients with H. pylori infection, bismuth quadruple therapy (BQT) for 14 days is the preferred regimen when antibiotic susceptibility is unknown. Rifabutin triple therapy or potassium-competitive acid blocker dual therapy for 14 days is a suitable empiric alternative in patients without penicillin allergy. In treatment-experienced patients with persistent H. pylori infection, "optimized" BQT for 14 days is preferred for those who have not been treated with optimized BQT previously and for whom antibiotic susceptibility is unknown. In patients previously treated with optimized BQT, rifabutin triple therapy for 14 days is a suitable empiric alternative. Salvage regimens containing clarithromycin or levofloxacin should only be used if antibiotic susceptibility is confirmed. The CPG also addresses who to test, the need for universal post-treatment test-of-cure, and the current evidence regarding antibiotic susceptibility testing and its role in guiding the choice of initial and salvage treatment. The CPG concludes with a discussion of proposed research priorities to address knowledge gaps and inform future management recommendations in patients with H. pylori infection from North America.
- Clinical chorioamnionitis at term: definition, pathogenesis, microbiology, diagnosis, and treatment.
Clinical chorioamnionitis, the most common infection-related diagnosis in labor and delivery units, is an antecedent of puerperal infection and neonatal sepsis. The condition is suspected when intrapartum fever is associated with two other maternal and fetal signs of local or systemic inflammation (eg, maternal tachycardia, uterine tenderness, maternal leukocytosis, malodorous vaginal discharge or amniotic fluid, and fetal tachycardia). Clinical chorioamnionitis is a syndrome caused by intraamniotic infection, sterile intraamniotic inflammation (inflammation without bacteria), or systemic maternal inflammation induced by epidural analgesia. In cases of uncertainty, a definitive diagnosis can be made by analyzing amniotic fluid with methods to detect bacteria (Gram stain, culture, or microbial nucleic acid) and inflammation (white blood cell count, glucose concentration, interleukin-6, interleukin-8, matrix metalloproteinase-8). The most common microorganisms are Ureaplasma species, and polymicrobial infections occur in 70% of cases. The fetal attack rate is low, and the rate of positive neonatal blood cultures ranges between 0.2% and 4%. Intrapartum antibiotic administration is the standard treatment to reduce neonatal sepsis. Treatment with ampicillin and gentamicin have been recommended by professional societies, although other antibiotic regimens, eg, cephalosporins, have been used. Given the importance of Ureaplasma species as a cause of intraamniotic infection, consideration needs to be given to the administration of antimicrobial agents effective against these microorganisms such as azithromycin or clarithromycin. We have used the combination of ceftriaxone, clarithromycin, and metronidazole, which has been shown to eradicate intraamniotic infection with microbiologic studies. Routine testing of neonates born to affected mothers for genital mycoplasmas could improve the detection of neonatal sepsis. Clinical chorioamnionitis is associated with decreased uterin
Evolving epidemiological data and increasing antibiotic resistance mandate an update of the European and North American Societies of Pediatric Gastroenterology, Hepatology and Nutrition guidelines. Certainty of evidence and strength of recommendations were rated by experts according to the Grading of Recommendation Assessment, Development, and Evaluation approach. PICO (patient population, intervention, comparator, and outcome) questions were developed and voted on by the group. Recommendations were formulated using the Evidence to Decision framework. The current literature supports many of the previous recommendations and several new recommendations. Invasive testing with strain antimicrobial susceptibility analysis is recommended for the diagnosis and selection of eradication therapy for H. pylori infection. Molecular methods are acceptable for detection of infection and of antibiotic resistance in gastric biopsy specimens. Reliable, noninvasive tests can be used as a screening method for children with history of gastric cancer in a first-degree relative. When investigating causes of chronic immune thrombocytopenic purpura, testing for H. pylori is no longer recommended. When investigating other diseases such as inflammatory bowel disease, celiac disease, or eosinophilic esophagitis, specific diagnostic biopsies for H. pylori infection are not indicated. However, if H. pylori is an incidental finding, treatment may be considered after discussing the risks and benefits. Treatment should be based on antibiotic antimicrobial susceptibility testing and, if unavailable, regimens containing clarithromycin should be avoided. Due to decreasing prevalence of infection, increasing challenges with antibiotic resistance, and emerging evidence regarding complications of infection, clinicians must be aware of these recommended changes to appropriately manage H. pylori infection and its clinical sequelae in children.
Group A beta-hemolytic streptococcal pharyngitis is a common infection responsible for more than 6 million office visits in the United States annually. Only 10% of adults seeking care for a sore throat have group A beta-hemolytic streptococcal pharyngitis; however, 60% or more are prescribed antibiotics. Guidelines recommend using clinical decision rules to assess the risk of group A beta-hemolytic streptococcal infection, followed by rapid antigen testing if a diagnosis is unclear, before prescribing antibiotics. Fever, tonsillar exudate, cervical lymphadenitis, and patient ages of 3 to 15 years increase clinical suspicion. A cough is more suggestive of a viral etiology. The limited history used in these decision rules is amenable to virtual visits. After a negative rapid antigen test result, a throat culture is recommended in children and adolescents. Penicillin and amoxicillin are first-line antibiotics, with a recommended course of 10 days; first-generation cephalosporins are recommended for patients with nonanaphylactic allergies to penicillin. There is significant resistance to azithromycin and clarithromycin in some parts of the United States. Steroids are not recommended for symptomatic treatment. Patients with worsening symptoms after appropriate antibiotic initiation or with symptoms lasting 5 days after the start of treatment should be reevaluated. Tonsillectomy is rarely recommended as a preventive measure: seven episodes of streptococcal pharyngitis in 1 year, five episodes in each of the past 2 years, or three episodes in each of the past 3 years are commonly used thresholds for considering surgery.
The infection caused by Helicobacter pylori is the most common on the planet, affecting half of the global population. It is usually transmitted during childhood and persists for life if untreated. It is the primary cause of chronic gastritis, peptic ulcer, and gastric cancer. In young dyspeptic patients without alarm symptoms, the test-and-treat strategy (detection of H. pylori through a non-invasive test and subsequent eradication) is the preferred approach. The causal role of the infection in the development of gastric adenocarcinoma provides an opportunity to implement preventive strategies. The infection can be diagnosed through invasive methods (requiring endoscopy, such as the rapid urease test or histology) and non-invasive methods (such as the breath test or stool antigen test). The treatment for H. pylori combines a proton pump inhibitor with several antibiotics or bismuth salts.